Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04098744Phase 2Recruiting

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Role: lead

NCT06075264Phase 2Recruiting

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Role: lead

NCT05555862Phase 2Active Not Recruiting

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

Role: lead

NCT06206564Phase 2Recruiting

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

Role: lead

NCT03792516Phase 1Completed

Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)

Role: collaborator

NCT03100045Phase 1Completed

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

Role: collaborator

NCT02354534Phase 1Completed

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Role: collaborator

All 7 trials loaded